UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000018758
Receipt number R000021696
Scientific Title The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.
Date of disclosure of the study information 2015/08/24
Last modified on 2023/08/27 09:47:40

No. Disposal Last modified on Item of update
1 Insert 2015/08/21 18:53:56
2 Update 2017/08/22 22:55:44 Last name of contact person
Last name of contact person
Email
Name of primary person or sponsor
Organization
Category of Funding Organization
3 Update 2019/08/24 16:44:23 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
4 Update 2019/08/24 16:47:43 Recruitment status
Date of IRB
Anticipated trial start date
Last follow-up date
5 Update 2023/08/27 09:37:46 Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other related information
6 Update 2023/08/27 09:47:40 Recruitment status